Zealand Pharma A/S (OTCMKTS:ZLDPF) Releases Earnings Results, Beats Expectations By $0.33 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) released its quarterly earnings data on Thursday. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.33, Zacks reports. Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 67.06%.

Zealand Pharma A/S Stock Up 1.6%

Shares of ZLDPF stock traded up $1.28 during midday trading on Thursday, reaching $80.00. 150 shares of the stock were exchanged, compared to its average volume of 788. Zealand Pharma A/S has a 1 year low of $49.98 and a 1 year high of $115.06. The firm has a market cap of $5.68 billion, a PE ratio of 5.62 and a beta of 0.71. The company’s 50 day moving average is $72.86 and its two-hundred day moving average is $65.78. The company has a current ratio of 15.09, a quick ratio of 15.08 and a debt-to-equity ratio of 0.02.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Zacks Research upgraded shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 15th. Wells Fargo & Company upgraded Zealand Pharma A/S to a “strong-buy” rating in a research report on Thursday, July 24th. Five equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Zealand Pharma A/S has a consensus rating of “Strong Buy”.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.